Episode 62: Apixaban Plasma Levels in Patients with HeartMate 3
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Episode 62: Apixaban Plasma Levels in Patients with HeartMate 3
-
Narrado por:
-
De:
Acerca de esta escucha
Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “Apixaban plasma levels in patients with HeartMate 3 support.”
As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom’s work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support.
The episode explores:
- The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors
- Encouraging findings from the study and what clinical practices might need to change if introducing apixaban
- Additional studies exploring DOACs in LVAD patients
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients.
Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.